Navigation Links
Increased glucose level is a strong risk factor for colorectal cancer
Date:11/1/2007

Bethesda, MD (November 1, 2007) Diabetes is a very common illness that affects more than 20 million people in the U.S. and it is estimated an additional 54 million Americans have pre-diabetes, a condition that occurs when a person's blood glucose levels are higher than normal but not high enough for a diagnosis of type 2 diabetes. Therefore, it is important to determine whether glucose and insulin levels are associated with a higher risk of colon polyps, the precursor lesions to colon cancer. According to the results of a study published in Gastroenterology, patients with high levels of insulin and glucose are at increased risk of developing recurrent colorectal adenomas, or tumors, with elevated glucose providing the strongest risk factor for recurrence of these lesions.

This is the first study to determine whether elevated glucose or insulin as measured when or shortly after a patient has had polyps removed during a baseline colonoscopy procedure increases their risk for subsequent recurrence of pre-cancerous growths in the colon, according to Andrew Flood, PhD, of the University of Minnesota and lead author of the study. The results of our study have important clinical implications with respect to maintenance of glycemic control in patients with a history of colorectal polyps.

In particular, study subjects who had even modestly impaired fasting glucose (an early sign of insulin resistance, itself a precursor of diabetes) had an especially large increased risk of recurrence of the types of polyps that are most likely to progress to invasive cancer. Therefore, the clinical management of glycemic control is important in reducing the risk of tumor recurrence and colorectal cancer. The glucose levels observed by researchers in the Polyp Prevention Trial, of which this study was a subset analysis, and the levels of exposure that led to the increased risk, were not unusually elevated. Researchers used a glucose concentration of 99 mg/dl as the cut point for the patients in the high group in the study; a fasting blood glucose level between 100 and 125 mg/dl signals pre-diabetes. The levels used in the study are reflective of those in the general U.S. population, therefore it is important to note that even a modest elevation of fasting glucose can affect a patients risk of colorectal cancer.

Patients who presented with the highest levels of both insulin and glucose had an approximately 50 percent increased risk of colorectal tumor recurrence. The Polyp Prevention Trial found a recurrence for colorectal tumors of 39.6 percent over four years, meaning the recurrence rate in this subset of patients represents a large increase in absolute risk. Patients who had a high concentration of glucose experienced more than 2.4 times increased odds of advanced tumor recurrence. The subjects with the highest glucose concentration also tended to be slightly older and have higher body mass index (BMI) and waist to hip ratios. Additionally, they were more likely to be male, current smokers, a member of a minority group and less likely to have advanced beyond a high school education. For those without a family history of colorectal cancer, researchers observed an even greater risk with elevated concentrations of insulin and glucose compared to the overall study population.

More than 1,905 patients from the Polyp Prevention Trial completed the study protocol, of which 375 matched pairs, or 750 patients, were included in this subset analysis. The patients were matched for gender and age within five years among trial participants who had recurrent adenomas and stored serum. The Polyp Prevention Trial was a clinical trial headed by the National Cancer Institute conducted with 2,079 men and women to determine the effect of a low-fat, high-fiber, high fruit/vegetable eating plan on the recurrence of precancerous polyps in the colon and rectum. Every participant had been diagnosed with a polyp within the previous six months, which was removed at colonoscopy.


'/>"/>

Contact: Aimee Frank
media@gastro.org
301-941-2620
American Gastroenterological Association
Source:Eurekalert

Related medicine news :

1. Use of Cellular Phones associated with Increased risk of Brain Tumors
2. Mortality increased in Sporting enthusiasts!
3. Increased Heart Attack Risk From Celebrex,Vioxx
4. Allergy Risk Increased by Kerosene Use
5. Strokes increased during squatting
6. Asthmatics at increased risk of lung cancer
7. Renal problem increased
8. Fewer teeth & Increased Ischemic Stroke risk
9. Risk of hemorrhagic stroke increased in smoking individuals
10. Young Smokers at Increased Risk Of Developing a Heart Attack
11. Women With Diabetes At Increased Risk Of Developing Cognitive Impairment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Island, NY (PRWEB) , ... February 11, 2016 ... ... has enhanced and updated its hallmark resource, Infusion Therapy Standards of Practice, to ... leader in vein illumination with an estimated 85% share of the market, facilitates ...
(Date:2/11/2016)... ... February 11, 2016 , ... The annual list showcases the 20 Most Promising ... team dedication and commitment to the SharePoint ecosystem. A panel of experts and ... goal is to recognize and promote technology entrepreneurship. , The survey was made ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... dynamometers and ergoFET force gauges used in physical therapy, occupational therapy and sports ... sensor for resistance cord exercise and therapy, introduces its new microFET Digital Pinch ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... coverage results in significantly higher rates of several common cancer screenings, especially among ... in better outcomes and survival rates. , The study,“What Does Medicaid Expansion ...
(Date:2/10/2016)... ... February 10, 2016 , ... Sherly Sulaiman, certified clinical ... of therapeutic sessions to help Los Angeles-area actors cope with rejection, improve their ... series, known as “Mindfulness for Actors and Artists,” has been featured in ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Fla. , Feb. 11, 2016 PLAD, ... started out 2016 with sales exceeding company targets, are ... have received their trademark from the United States Patent ... Bobby Clark , Chief Executive Officer of PLAD, Inc.  ... of Pennsylvania with two new ...
(Date:2/11/2016)... Feb. 11, 2016  Delcath Systems, Inc. (NASDAQ: ... device company focused on oncology with an emphasis ... cancers, announces the engagement of Lars E. ... Medical Consultant. Dr. Birgerson will provide strategic medical ... operations team to help ensure timely facilitation of ...
(Date:2/11/2016)... ENGLEWOOD, Colo. , Feb. 11, 2016  Aytu ... on developing treatments for urological and related conditions, announced ... for the second fiscal quarter of 2016 on Tuesday, ... will review recent accomplishments and provide an overview of ... financial results for the quarter ended December 31, 2015. ...
Breaking Medicine Technology: